image credit: Bamboo Works
Key Takeaways:
Early clinical data for the company's pan-KRAS inhibitor indicate the targeted cancer drug is safe and effective
Revenue tumbled in 2025 but Jacobio is projecting a profit for this year and a surging cash balance
Investors in Chinese drug developers have tended to focus on product pipelines and collaboration deals. But now they are paying more attention to the clinical data for emerging drugs and the prospects for global sales in the future.
Jacobio Pharmaceuticals Group Co. Ltd. (1167.HK) released its 2025 annual results on March 10 and disclosed early clinical data for a candidate drug targeting gene mutations associated with a range of cancers.
Jacobio's product in progress, the pan-KRAS inhibitor JAB-23E73, was the subject of a development deal with AstraZeneca late last year. With the $100 million upfront payment from that collaboration about to flow into earnings, the company has predicted it will land in the black in 2026.
Last year already marked a commercial milestone for Jacobio, when another of its drugs was approved for sale in China as a treatment for a type of lung cancer. The internally developed drug, Glecirasib, was cleared for patients carrying KRAS G12C mutations who had already received at least one round of cancer therapy.
Jacobio had already teamed up with Allist Pharmaceuticals (688578.SH) in 2024 to accelerate the drug's market launch, with the partner taking responsibility for China sales. The medication was added to China's National Reimbursement Drug List in December 2025, clearing the way for Jacobio to receive a milestone payment of 53.5 million yuan ($8 million) along with a share of product revenue.
Aside from the progress with Glecirasib, a clinical update on the pan-KRAS inhibitor JAB-23E73 was the most striking feature of the earnings ...
